Zevra Q1 2022 Earnings Report
Key Takeaways
KemPharm reported revenue of $4.0 million for Q1 2022, compared to $12.1 million in Q1 2021. The net loss attributable to common stockholders for Q1 2022 was ($1.9) million, or ($0.05) per basic and diluted share, compared to a net loss of ($47.7) million, or ($2.49) per basic and diluted share for the same period in 2021. Total cash, cash equivalents, marketable securities, and long-term investments were $119.1 million as of March 31, 2022.
Filed Investigational New Drug (IND) application with U.S. Food and Drug Administration (FDA) for KP1077, a serdexmethylphenidate (SDX)-based product candidate for idiopathic hypersomnia (IH).
Initiation of a Phase 2 trial (KP1077.D01) expected in the second half of 2022, with a second trial in patients with narcolepsy expected to begin the quarter following start of KP1077.D01.
Dosed first patient in Phase 1 clinical trial evaluating cardiovascular safety of SDX compared to immediate-release and long-acting formulations of Ritalin® (racemic methylphenidate).
Total cash, cash equivalents, marketable securities and long-term investments was $119.1 million as of March 31, 2022
Zevra
Zevra
Forward Guidance
Existing cash, cash equivalents, marketable securities and long-term investments are expected to be sufficient to continue operations through and beyond 2025.